TNF-NF-kappaB signaling mediates excessive somnolence in hemiparkinsonian rats.
Daytime somnolence is common in patients with Parkinson's disease (PD); however there is a lack of understanding of the cellular mechanisms involved in mediating these effects. It has been hypothesized that microglial activation and the subsequent increase of pro-inflammatory cytokines play an important role in the pathogenesis of PD. Because some cytokines are involved in the regulation of sleep, this study was designed to determine if tumor necrosis factor (TNF) and interleukin-1beta (IL-1beta), mediate daytime somnolence in the proteasome inhibitor (MG-132)-induced hemiparkinsonian rat model. Our results indicated that microglial activation caused the loss of dopaminergic neurons in the substantia nigra, and the expression of TNF-alpha, but not IL-1beta, increased in the midbrain and hypothalamus in MG-132-induced hemiparkinsonian rats. Slow-wave sleep (SWS) increased after the induction of hemiparkinsonism, but rapid eye movement (REM) sleep was not consistently altered. Application of the TNF receptor fragment (TNFRF) blocked hemiparkinsonism-induced SWS alteration, whereas the IL-1 receptor antagonist (IL-1ra) exhibited no effect. Increased nuclear translocation of NF-kappaB in the midbrain, and the blockade of SWS enhancement in MG-132-induced hemiparkinsonian rats by an inhibitor of NF-kappaB activation indicate that the TNF-NF-kappaB cascade is a critical mediator of MG-132 hemiparkinsonian-induced sleep alteration. This observation suggests potential therapeutic interventions to target the excessive daytime somnolence in patients with PD.
Lu
Chin-Yu
CY
Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan.
Yi
Pei-Lu
PL
Tsai
Chon-Haw
CH
Cheng
Chiung-Hsiang
CH
Chang
Han-Han
HH
Hsiao
Yi-Tse
YT
Chang
Fang-Chia
FC
D000818:Animals; D039481:CD11b Antigen / Q000378:metabolism; D015853:Cysteine Proteinase Inhibitors / Q000633:toxicity; D004195:Disease Models, Animal; D006970:Disorders of Excessive Somnolence / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology; D004569:Electroencephalography / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D007839:Functional Laterality / Q000502:physiology*; D005786:Gene Expression Regulation / Q000187:drug effects; D007976:Leupeptins / Q000633:toxicity; D008297:Male; D017628:Microglia / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D046529:Microscopy, Electron, Transmission / Q000379:methods; D016328:NF-kappa B / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000150:complications*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D018709:Statistics, Nonparametric; D013378:Substantia Nigra / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D039481:CD11b Antigen; D015853:Cysteine Proteinase Inhibitors; D004791:Enzyme Inhibitors; D007976:Leupeptins; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; D014446:Tyrosine 3-Monooxygenase; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde